CRT-123 A Novel Nano Particle Sirolimus Delivery Via Coated Balloon

Sojitra, Prakash; Yazdani, Saami K.; Otsuka, Fumiyuki; Doshi, Manish; Kolodgie, Frank D.; Virmani, Renu

doi:10.1016/j.jcin.2013.01.042

Cited by 8 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, adding further metal struts may also modify the bifurcation carina. Compared to paclitaxel, sirolimus is less lipophilic, has a wider therapeutic window (8) and the unique nano-encapsulation process of the SCB with the phospholipid drug carrier allows an improved drug retention profile and bioavailability in atherosclerotic or restenotic lesions (2). Furthermore the latest-generation monorail delivery system, compatible with 5-Fr guiding catheters, the low-profile distal tip and the rigid hypotube, warrant an high deliverability and trackability, and make it possible to use 2 balloons contemporarily during kissing balloon inflation, reducing the risk of struts distortion with a normal 2-step inflation, as previously demonstrated by Shetty et al [9].…”

Section: Discussionmentioning

confidence: 99%

“…In April 2016 the first sirolimus-coated balloon (SCB), Magic Touch (Envision Scientific PVT, India), obtained the CE Mark. This SCB is the first to elute sirolimus, thanks to a phospolipid nanocarrier system that allows long term drug retention in the vessel wall [2]. We here present the first case in Europe of ULM bifurcation ISR treated with a kissing-balloon technique using two SCBs.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

New Sirolimus-Coated Ballon for Complex Unprotected Left Main Distal Bifurcation

Cortese¹

2018

BJSTR

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

New Sirolimus-Coated Ballon for Complex Unprotected Left Main Distal Bifurcation

Cortese¹

2018

BJSTR

View full text Add to dashboard Cite

“…A nominal drug dose is ~1.27 µg/mm 2 . Pre-clinical assessment of safety and efficacy showed that the most appropriate identification of the best nanoparticle structure is associated with an extremely efficient drug transfer to all layers of the vessel wall, achieving high tissue concentrations that persisted for days after the application, with low systemic drug leaks [29]. The Nanoluté registry was designed to observe the clinical performance of Magic Touch for the treatment of coronary de novo and restenotic lesions [30].…”

Section: Sirolimus-eluting Balloonsmentioning

confidence: 99%

Safety Issues Associated with Paclitaxel-Eluting Balloons and Progress of Sirolimus-Eluting Balloons

Yin¹,

Wang²,

Wang³

et al. 2020

IJCTS

View full text Add to dashboard Cite

Drug eluting balloons (DEBs) are semi-compliant angioplasty balloons covered with an antiproliferative drug which is rapidly released locally into the vessel wall during balloon contact. Their advantages include a broader area of drug contact, more homogenous drug-tissue transfer for stent-based local drug delivery, no implant leaving as well as shortened dual antiplatelet therapy. DEBs application was first recommended by the European Society of Cardiology (ESC) and European Association for Cardio-Thoracic Surgery (EACTS) guidelines for the treatment of in-stent restenosis (ISR) after prior bare-metal stent (BMS) (Class IIA, Level B) in 2010. Since then, rapid progress has been made in the use of DEBs for treatment of in-stent restenosis, bifurcation, small vessel diseases, and other de novo occlusive coronary artery diseases even the symptomatic peripheral arterial disease. However, a meta-analysis of 28 randomized controlled trials (RCTs) with 4663 patients investigating paclitaxel-coated devices (DEBs & drug-eluting stent) in the femoral and/or popliteal arteries showed a highly significant association between risk of death and paclitaxel exposure in a dose-time-dependent manner. Safety issues associated with clinical application of paclitaxel DEBs in femoropopliteal artery was widely discussed. This study reviewed the issues, different molecular mechanisms of paclitaxel and sirolimus in antiproliferative effects, and progress of sirolimus-eluting balloons.

show abstract

“…Sirolimus, a lipophilic drug, is formulated in nanoparticle delivery systems via coated balloons to achieve rapid release. Sirolimusnanoparticle-coated balloons have been tested with in vitro and in vivo models [69].…”

Section: Sirolimusmentioning

confidence: 99%

Drug-eluting balloon: design, technology and clinical aspects

2018

View full text Add to dashboard Cite

A drug-eluting balloon is a non-stent technology in which the effective homogenous delivery of anti-proliferative drugs is processed by the vessel wall through an inflated balloon. This is done to restore luminal vascularity in order to treat atherosclerosis, in-stent restenosis and reduce the risk of late thrombosis without implanting a permanent foreign object. The balloon technology relies on the concept of targeted drug delivery, which helps in the rapid healing of the vessel wall and prevents the proliferation of smooth muscle cells. Several drug eluting devices in the form of coated balloons are currently in clinical use, namely DIOR, PACCOCATH, SeQuentPlease and IN.PACT™. The device varies in terms of the material used for making the balloon, the coating techniques, the choice of coated drug and the release pattern of the drug at the site. This review gives an insight into the evolution, rationale and comparison of the marketed drug-eluting balloons. Here, different coating techniques have been analysed for the application and critical analysis of available DEB technologies, and a technical comparison has been done.

show abstract

CRT-123 A Novel Nano Particle Sirolimus Delivery Via Coated Balloon

Cited by 8 publications

References 0 publications

New Sirolimus-Coated Ballon for Complex Unprotected Left Main Distal Bifurcation

New Sirolimus-Coated Ballon for Complex Unprotected Left Main Distal Bifurcation

Safety Issues Associated with Paclitaxel-Eluting Balloons and Progress of Sirolimus-Eluting Balloons

Drug-eluting balloon: design, technology and clinical aspects

Contact Info

Product

Resources

About